NASDAQ · Biotechnology · USD
Savara Inc. (SVRA) Stock Analysis
Savara Inc. (SVRA) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.
Price History
No price data available
Hover for the daily close. The dotted line marks the period open.
SVRA Key Statistics
As of Sep 4, 2026Trading
- Open
- $5.32
- Previous Close
- $5.37
- Day's Range
- 5.31–5.39
- 52-Week Range
- 3.34–7.01
- Volume
- 625.20K
- BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
- 0.25
Valuation
- Market Cap
- $1.10B
- P/E Ratio
- unprofitable
- EPS (ttm)Profit attributable to each share over the last twelve months.
- −0.58
Financials (FY)
- Revenue (FY)
- $0.00
- Net Income (FY)
- −$118.84M
- Profit marginThe share of revenue left as profit after all costs and taxes.
- 0.00%
- Shares Outstanding
- 205.46M
- 1-Year Return
- +50.00%
Dividend and dates
- Earnings Date
- November 11, 2026estimated
- Avg Volume
- 1.80M
Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.
SVRA Stock Return by Calendar Year
Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.
| Year | Return |
|---|---|
| 2026 (partial year) | −10.95% |
| 2025 | +96.42% |
| 2024 | −34.68% |
| 2023 | +203.23% |
| 2022 | +25.00% |
| 2021 | +7.83% |
| 2020 | −74.33% |
| 2019 | −40.82% |
| 2018 | −48.99% |
| 2017 (partial year) | +69.41% |
As of September 4, 2026.
SVRA Revenue and Earnings by Fiscal Year
FY ends December| Fiscal year | Revenue | Net income | Net margin |
|---|---|---|---|
| 2025 | $0.00 | −$118.84M | — |
| 2024 | $0.00 | −$95.88M | — |
| 2023 | $0.00 | −$54.70M | — |
| 2022 | $0.00 | −$38.15M | — |
| Fiscal year | Revenue | Gross profit | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| 2025 | $0.00 | — | −$122.76M | −$118.84M | — |
| 2024 | $0.00 | — | −$102.40M | −$95.88M | — |
| 2023 | $0.00 | — | −$59.21M | −$54.70M | — |
| 2022 | $0.00 | — | −$38.04M | −$38.15M | — |
Annual figures as reported, in the company's reporting currency. As of December 31, 2025.
SVRA Valuation vs Biotechnology Median
Median of 656 stocks| Metric | SVRA | Biotechnology median | vs median |
|---|---|---|---|
| Profit margin | 0.00% | 0.00% | 0.0 pts above |
Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.
Recent News
Savara Announces Acceptance Of Oral Presentation, Two Poster Presentations From Phase 3 IMPALA-2 Clinical Studies At ERS Congress
BenzingaSavara Says MOLBREEVI MAAs Under Review By EMA And U.K's MHRA; Decisions Expected Q1 2027 And Q4 2026, Respectively; European And Australian Patent Offices Grant MOLBREEVI Patents Until March 2041
BenzingaSavara Q2 EPS $(0.16) Misses $(0.14) Estimate
BenzingaSavara: High Potential Binary Bet Cruising To PDUFA After 3 Month Speed Bump
SeekingAlpha
News provided by third-party sources. Not financial advice.
Analysis
Data-derivedEvery figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.
Related Biotechnology Stocks
Vertex Pharmaceuticals Incorporated
$138.42B
REGNRegeneron Pharmaceuticals, Inc.
$85.22B
ARGXargenx SE
$64.25B
MRNAModerna, Inc.
$58.11B
RVMDRevolution Medicines, Inc.
$45.01B
ONCBeOne Medicines AG
$40.53B
Popular Healthcare Stocks
Eli Lilly and Company
$1.02T
JNJJohnson & Johnson
$663.28B
ABBVAbbVie Inc.
$453.19B
MRKMerck & Co., Inc.
$370.89B
UNHUnitedHealth Group Incorporated
$356.47B